Sugi Predict

Sugi Predict / Compounds / SCHEMBL4404940

SCHEMBL4404940

SCHEMBL4404940

CCOc1cccc(-c2ccc(F)c([N+](=O)[O-])c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ RXRA P19793 1/20 0.50
▸ RXRB P28702 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ LMNA P02545 1/20 0.49
▸ PTGES O14684 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ DHODH Q02127 2/20 0.43
▸ FGFR1 P11362 1/20 0.43
▸ FGFR2 P21802 1/20 0.43
▸ FGFR3 P22607 1/20 0.43
▸ FFAR1 O14842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4418072 0.85 ABCG2 (0.54) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL29739504 0.84 MAPT (0.62) MAPTMAPK1MEN1RECQLKMT2A
SCHEMBL1189617 0.84 MAPT (0.62) MAPTMAPK1MEN1RECQLKMT2A
SCHEMBL4413254 0.79 RXRA (0.54) MAPTMAPK1MEN1RECQLKMT2A
SCHEMBL11579276 0.77 ALDH1A1 (0.67) MAPTMAPK1MEN1RECQLKMT2A
SCHEMBL4408884 0.77 ALDH1A1 (0.54) MAPTMAPK1MEN1RECQLKMT2A
SCHEMBL2654598 0.77 ALDH1A1 (0.50) MAPTMAPK1MEN1RECQLKMT2A
SCHEMBL6313832 0.76 ALDH1A1 (0.53) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL2650363 0.76 CRHBP (0.58) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL29426410 0.75 RXRA (0.66) MAPTMAPK1RXRARXRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2020408-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors Sugen, Inc. (US) 2009-02-04 — — EP disclosed
US-7189721-B2 Bicyclic protein kinase inhibitors SUGEN INC. (US) 2007-03-13 — — US disclosed
US-7119090-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2006-10-10 — — US disclosed
US-6878733-B1 Formulations for pharmaceutical agents ionizable as free acids or free bases SUGEN, INC. (US) 2005-04-12 — — US disclosed
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 — — US disclosed
US-20040106630-A1 Bicyclic protein kinase inhibitors SUGEN, INC. 2004-06-03 — — US disclosed
US-20040106618-A1 Bicyclic protein kinase inhibitors SUGEN, INC. 2004-06-03 — — US disclosed
US-20040067531-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds SUGEN, INC. 2004-04-08 — — US disclosed
US-6696448-B2 USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER, DIABETES, AUTOIMMUNE DISORDERS, HYPERPROLIFERATIVE DISORDERS SUCH AS RHEUMATOID ARTHRITIS AND INFLAMMATORY DISORDERS SUGEN, INC. 2004-02-24 — — US disclosed
US-6696463-B2 FOR THERAPY OF CELL PROLIFERATION, DIFFERENTIATION OR GROWTH DISORDERS, CANCER SUGEN, INC. 2004-02-24 — — US disclosed
US-20010056094-A1 Anticarcinogenic agents TANG PENG CHO (US) 2001-12-27 — — US disclosed
US-6316429-B1 ENZYME INHIBITORS MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER. SUGEN, INC. 2001-11-13 — — US disclosed
US-6313158-B1 THERAPY AND PROPHYLAXIS OF CANCER SUGEN, INC. 2001-11-06 — — US disclosed
WO-2001037820-A2 IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS SUGEN, INC. (US) 2001-05-31 — — WO disclosed
EP-1066257-A2 HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE Sugen, Inc. (US) 2001-01-10 — — EP disclosed
WO-2000008202-A9 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN INC (US) 2000-07-27 — — WO disclosed
WO-1999048868-A9 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN INC (US) 2000-04-20 — — WO disclosed
US-6051593-A USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER SUGEN, INC. (US) 2000-04-18 — — US disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 — — WO disclosed
WO-1999048868-A2 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN, INC. (US) 1999-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010056094-A1 Anticarcinogenic agents GSTK1, CDC42BPG, GLS MAPT 4728/4885MAPK1 494/4885MEN1 4409/4885
US-20040067531-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds ABL1, LCK, PNCK MAPT 1859/4885MAPK1 413/4885MEN1 3839/4885
US-20040106618-A1 Bicyclic protein kinase inhibitors MAP3K20, MAP4K3, MAP4K2 MAPT 3296/4885MAPK1 219/4885MEN1 3295/4885
US-20040106630-A1 Bicyclic protein kinase inhibitors MAP3K20, MAP4K3, MAP4K2 MAPT 3296/4885MAPK1 219/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.